Case closed: Neutrons settle 40-year debate on enzyme for drug design
Filter News
Area of Research
- (-) Nuclear Science and Technology (2)
- Biology and Environment (10)
- Clean Energy (47)
- Computational Biology (1)
- Computational Engineering (1)
- Fusion and Fission (1)
- Isotopes (2)
- Materials (15)
- Materials for Computing (5)
- National Security (3)
- Neutron Science (9)
- Supercomputing (12)
- Transportation Systems (2)
News Type
News Topics
- (-) Biomedical (2)
- 3-D Printing/Advanced Manufacturing (2)
- Advanced Reactors (6)
- Bioenergy (1)
- Computer Science (5)
- Cybersecurity (2)
- Decarbonization (1)
- Fusion (2)
- Grid (1)
- Isotopes (3)
- Materials Science (1)
- Molten Salt (3)
- Neutron Science (3)
- Nuclear Energy (17)
- Physics (2)
- Quantum Science (4)
- Space Exploration (4)
- Sustainable Energy (1)
- Transformational Challenge Reactor (1)
Media Contacts
Oak Ridge National Laboratory researchers have discovered a better way to separate actinium-227, a rare isotope essential for an FDA-approved cancer treatment.
The Department of Energy’s Oak Ridge National Laboratory is now producing actinium-227 (Ac-227) to meet projected demand for a highly effective cancer drug through a 10-year contract between the U.S. DOE Isotope Program and Bayer.